contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pharma-equity-group-takeaways-from-q3-event

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Henrik Ekman

CEO, Sweden

Claus Thestrup

Pharma Equity Group utvecklar läkemedel för behandling av allvarliga och livshotande inflammatoriska sjukdomar för vilka det för närvarande inte finns någon adekvat behandling. Bolaget använder ompositionering av befintliga läkemedel och tar läkemedelskandidater till ett kliniskt fas III-stadium, varefter de överlämnas till en strategisk partner som kommer att slutföra utvecklingen av produkterna och föra ut dem på marknaden, antingen självständigt eller i samarbete med bolaget.

Pharma Equity Group

Pharma Equity Group: Takeaways from Q3 event

Pharma Equity Group: Takeaways from Q3 event
Shares in Pharma Equity Group rose 4 % yesterday following the release of the company&rsquo;s 3rd quarter report showing an expected net loss of DKK 4,4 million due to the company&rsquo;s ongoing development of its pipeline product candidates as there is currently no revenue and not expected to be any before 2025. The company reiterated their expectation of a net loss of DKK 18-22 million for the full year. As the cash position was only DKK 1,5 million by September 30th, the company has so far negotiated bridge financing of DKK 6,5 million but expect to seek up to DKK 20 million as the company await to receive the repayment of its receivables from Portinho SA valued at DKK 64 million in the 3rd quarter report. 
At the event Thomas K Sels&oslash; explained the technical reasons why the repayment still hasn&rsquo;t been made, but remained confident it is only a matter of time before it happens. 
At the event CMO Christopher Burton also gave an overview over the product pipeline and explained the concepts of the unique reposition strategy of Pharma Equity Group and presented a few highlights of each of the company&rsquo;s product candidates in the pipeline. Christopher Burton also commented on the release of positive preliminary data of its phase 2 study regarding its RNX-051 product candidate to treat colon cancer.
All in all, the report and the event presentation suggested that Pharma Equity Group remain on track to deliver on both its product development and financial expectations.
Listen to the interview in Danish: <a href="https://www.inderes.dk/videos/pharma-equity-group-praesentation-af-q3-2023" target="_blank" rel="noopener">PEG - Q3 and pipeline opdate</a> &nbsp;&nbsp;&nbsp;&nbsp;
Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 12:05 PM 17-11-2023.
&nbsp;